Alnylam Pharmaceuticals Inc ALNY:NASDAQ

Last Price$171.36NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/03/21
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$171.36 (189)
Ask (Size)$188.88 (1)
Day Low / HighN/A - N/A
Volume640.2 K
 

View Biotechnology IndustryPeer Comparison as of 12/03/2021

 

Alnylam Pharmaceuticals Inc ( NASDAQ )

Price: $171.36
Change: -11.49 (6.28%)
Volume: 640.2 K
4:00PM ET 12/03/2021
 
 

Bio-Techne Corp ( NASDAQ )

Price: $456.15
Change: -11.12 (2.38%)
Volume: 259.4 K
4:00PM ET 12/03/2021
 
 

Biomarin Pharmaceutical Inc ( NASDAQ )

Price: $82.95
Change: -1.73 (2.04%)
Volume: 1.3 M
4:00PM ET 12/03/2021
 
 

Repligen Corp ( NASDAQ )

Price: $262.88
Change: -5.94 (2.21%)
Volume: 299.3 K
4:00PM ET 12/03/2021
 
 

Incyte Corp ( NASDAQ )

Price: $65.78
Change: -0.85 (1.28%)
Volume: 2.6 M
4:00PM ET 12/03/2021
 

Read more news Recent News

Sector Update: Health Care Stocks Finishing Mixed This Afternoon
4:05PM ET 11/22/2021 MT Newswires

Health care stocks were mixed late Monday afternoon, with the NYSE Health Care Index rising 0.2% while the Health Care Select Sector SPDR ETF (XLV) slipped...

Sector Update: Health Care Stocks Drifting Near Unchanged Mark Monday
1:55PM ET 11/22/2021 MT Newswires

Health care stocks were mixed Monday afternoon, with the NYSE Health Care Index rising 0.1% while the Health Care Select Sector SPDR ETF (XLV) slipped...

Alnylam Pharmaceuticals Shares Rise After Goldman Sachs Upgrade
12:26PM ET 11/22/2021 MT Newswires

Alnylam Pharmaceuticals (ALNY) shares rose 6% Monday after Goldman Sachs upgraded the stock to buy from neutral. Goldman set a $273 share price target for...

Needham Adjusts Alnylam Pharmaceuticals' Price Target to $205 From $180, Reiterates Buy Rating
9:35AM ET 11/22/2021 MT Newswires

Alnylam Pharmaceuticals (ALNY) has an average rating of outperform and price targets ranging from $108 to $275, according to analysts polled by Capital IQ....

Company Profile

Business DescriptionAlnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. The firm's products include ONPATTRO, GIVLAARI, and OXLUMO. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA. View company web site for more details
Address675 West Kendall Street
Cambridge, Massachusetts 02142
Phone+1.617.551.8200
Number of Employees1,065
Recent SEC Filing11/12/20214
Chief Executive Officer & DirectorJohn M. Maraganore
President & Chief Operating OfficerYvonne L. Greenstreet
Executive VP, Chief Financial & Accounting OfficerJeffrey V. Poulton
President-Research & DevelopmentAkshay K. Vaishnaw

Company Highlights

Price Open$183.57
Previous Close$182.85
52 Week Range$121.98 - 212.00
Market Capitalization$20.5 B
Shares Outstanding119.6 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement02/10/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$7.01
Beta vs. S&P 500N/A
Revenue$74.9 M
Net Profit Margin-111.82%
Return on Equity-94.37%

Analyst Ratings as of 11/22/2021

Buy
15
Overweight
0
Hold
6
Underweight
2
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset